Sunday 18 October 2026
Export IKT’s income statement to Excel — free account
Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $260,500.00, up 111.1% from fiscal 2022. In the quarter to June 2026, EPS was flat and free cash flow fell 123.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
1.65
0.18
−9.84%
Follow IKT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(131.71%) | (36.05%) | (40.23%) | (51.96%) | |
| (113.51%) | (34.49%) | (38.09%) | (48.04%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(66.34%) | (28.09%) | (30.61%) | (39.87%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.28) | (0.28) | (0.21) | (0.24) | |
Free Cash Flow |
(25.63) | (27.80) | (35.74) | (42.61) | |
Capital Expenditures |
(0.01) | (0.01) | — | — | |
| Other line items | |||||
Cash ROIC |
(17.06%) | (7.91%) | (10.58%) | (13.64%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.54 | 0.58 | 0.70 | 0.70 | |
Depreciation/Fixed assets |
0.00 | 0.00 | — | — | |
Capex/Depreciation |
(0.20) | (0.22) | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.28) | (0.28) | (0.21) | (0.24) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates